½ÃÀ庸°í¼­
»óǰÄÚµå
1672804

¼¼°èÀÇ ´ã°ü¾Ï ½ÃÀå : Ä¡·á À¯Çüº°, À¯Åë ä³Îº°, Áö¿ªº°

Bile Duct Cancer Market, By Treatment Type , By Distribution Channel, By Geography

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Coherent Market Insights | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ ´ã°ü¾Ï ½ÃÀå ±Ô¸ð´Â 2025³â¿¡´Â 40¾ï 3,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ°í, 2032³â¿¡´Â 71¾ï 8,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2025³âºÎÅÍ 2032³â±îÁö CAGR 8.6%¸¦ ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

º¸°í ¹üÀ§ º¸°í¼­ ¼¼ºÎÁ¤º¸
±âÁØ ¿¬µµ 2024³â ½ÃÀå ±Ô¸ð(2025³â) 40¾ï 3,000¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2020-2024³â ¿¹Ãø ±â°£ 2025-2032³â
¿¹Ãø ±â°£ CAGR(2025-2032³â) : 8.60% ±Ý¾× ¿¹Ãø(2032³â) 71¾ï 8,000¸¸ ´Þ·¯
±×¸². ´ã°ü¾Ï Áö¿ªº° ½ÃÀå Á¡À¯À²(%)(2025³â)
Bile Duct Cancer Market-IMG1

´ã°ü¾ÏÀº ´ãµµ¾ÏÀ¸·Îµµ ¾Ë·ÁÁ® ÀÖÀ¸¸ç ´ã°ü¿¡ »ý±â´Â µå¹® À¯ÇüÀÇ ¾ÏÀÔ´Ï´Ù. ´ã°üÀº °£°ú ´ã³¶À» ¼ÒÀå¿¡ ¿¬°áÇÏ´Â °üÀÔ´Ï´Ù. ´ã°ü¾ÏÀº ´ã°ü¿¡ ´Ã¾î¼± ¼¼Æ÷¿¡ ÀÌ»óÀÌ »ý°Ü Á¦¾î ºÒ´ÉÀ¸·Î Áõ½ÄÇÏ¿© Á¾¾çÀ» Çü¼ºÇÔÀ¸·Î½á ¹ß»ýÇÕ´Ï´Ù. ´ã°ü¾ÏÀ» ¹ßº´ÇÏ´Â ÁÖ¿ä À§Çè ÀÎÀڷδ ¿ø¹ß¼º °æÈ­¼º ´ã°ü¿°(PSC), ¿°Áõ¼º Àå Áúȯ, °£ Ç÷çÅ©, ´ã°üÀÇ Æ¯Á¤ ¼±ÃµÀû ÀÌ»ó µîÀÌ ÀÖ½À´Ï´Ù. Áõ»óÀ¸·Î´Â Ȳ´Þ, °¡·Á¿òÁõ, º¹Åë, üÁß °¨¼Ò, Ǫ¸¥ Èò ´ëº¯ µîÀÌ ÀÖ½À´Ï´Ù. Áø´Ü¿¡´Â ÀϹÝÀûÀ¸·Î ÃÊÀ½ÆÄ °Ë»ç, CT ½ºÄµ, MRI ½ºÄµ µîÀÇ À̹ÌÁö °Ë»ç ¹× »ý°ËÀÌ ¼öÇàµË´Ï´Ù. Ä¡·á ¿É¼ÇÀº ¾ÏÀÇ ´Ü°è¿¡ µû¶ó ´Ù¸£¸ç ¼ö¼ú, ¹æ»ç¼± ¿ä¹ý, È­ÇÐ ¿ä¹ý, Ç¥Àû ¿ä¹ý µîÀÌ ÀÖ½À´Ï´Ù. ±×·¯³ª ´ã°ü¾ÏÀº Á¶±â ¹ß°ßÀÌ ¾î·Æ°í Á¾¾çÀÇ Áõ½ÄÀÌ ´À¸®±â ¶§¹®¿¡ »ýÁ¸À²ÀÌ ³·°í ¿¹ÈÄ ºÒ·®ÀÔ´Ï´Ù.

½ÃÀå ¿ªÇÐ :

¼¼°èÀÇ ´ã°ü¾Ï ½ÃÀåÀÇ ¼ºÀåÀº ÁÖ·Î PSC³ª °£Ç÷°½º °¨¿° µî À§Çè ÀÎÀÚÀÇ À¯º´·ü Áõ°¡°¡ °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ¹Ì±¹ Áúº´°ü¸®¿¹¹æ¼¾ÅÍ(CDC)¿¡ µû¸£¸é PSC´Â ¹Ì±¹¿¡¼­ ¾à 3¸¸ ¸íÀÌ ¾Î°í ÀÖ½À´Ï´Ù. ´ã°ü¾ÏÀÇ ÀÌÇØ ºÎÁ·À̳ª Áø´ÜÀÇ Áö¿¬µµ, ÁøÇà±â¿¡¼­ÀÇ Áø´Ü¿¡ ¿¬°áµÇ¾î, ±× °á°ú, ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. °Ô´Ù°¡ ´ã°ü¾ÏÀÇ Ä¡·á ¼ºÀûÀ» °³¼±Çϱâ À§ÇÑ Ç¥Àû ¾à¹° °³¹ßÀ» À§ÇÑ ¿¬±¸ ÀÚ±ÝÀÌ Áõ°¡Çϰí ÀÖ´Â °Íµµ ½ÃÀå °ü°èÀÚ¿¡°Ô À¯¸®ÇÑ ±âȸ¸¦ Á¦°øÇÒ °¡´É¼ºÀÌ ÀÖ½À´Ï´Ù. ±×·¯³ª Áúº´ ÀÎÁöµµ°¡ ³·°í ¼ö¼úÀÇ º¹À⼺ÀÌ ½ÃÀå ¼ºÀåÀ» ¹æÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

  • º» º¸°í¼­¿¡¼­´Â ¼¼°èÀÇ ´ã°ü¾Ï ½ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®ÇÏ¿© 2024³âÀ» ±âÁØ¿¬µµ·Î ÇÑ ¿¹Ãø±â°£(2025-2032³â) ½ÃÀå ±Ô¸ð ¹× ¿¬°£ Æò±Õ ¼ºÀå·ü(CAGR%)À» Á¦°øÇÕ´Ï´Ù.
  • ¶ÇÇÑ ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀûÀÎ ¼öÀÍ ±âȸ¸¦ ¹àÈ÷°í, ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¿¡ ´ëÇØ ¼³¸íÇÕ´Ï´Ù.
  • ¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÌ Ã¤¿ëÇÏ´Â °æÀï Àü·« µî¿¡ °üÇÑ Áß¿äÇÑ ÀλçÀÌÆ®µµ Á¦°øÇÕ´Ï´Ù.
  • ±â¾÷ ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, ¼º°ú, Àü·« µîÀÇ ¸Å°³º¯¼ö¸¦ ¹ÙÅÁÀ¸·Î ¼¼°è ´ã°ü¾Ï ½ÃÀå¿¡¼­ ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏÀ» Á¦°øÇÕ´Ï´Ù.
  • ÀÌ º¸°í¼­ÀÇ ÀλçÀÌÆ®¸¦ ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀÌ ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯Çü ¾÷±×·¹À̵å, ½ÃÀå È®´ë ¹× ¸¶ÄÉÆÃ Àü¼ú¿¡ ´ëÇÑ Á¤º¸¸¦ ±â¹ÝÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.
  • ¼¼°èÀÇ ´ã°ü¾Ï ½ÃÀå º¸°í¼­´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô Âü°¡ÀÚ, À繫 ºÐ¼®°¡ µî ÀÌ ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ Áö¿øÇÕ´Ï´Ù.
  • ÀÌÇØ°ü°èÀÚ´Â ¼¼°èÀÇ ´ã°ü¾Ï ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤ÀÌ ¿ëÀÌÇØÁý´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»çÀÇ ¸ñÀû ¹× ÀüÁ¦Á¶°Ç

  • Á¶»ç ¸ñÀû
  • ÀüÁ¦Á¶°Ç
  • ¾à¾î

Á¦2Àå ½ÃÀå Àü¸Á

  • º¸°í¼­ ¼³¸í
    • ½ÃÀå Á¤ÀÇ ¹× ¹üÀ§
  • ÁÖ¿ä ¿ä¾à
  • Coherent Opportunity Map(COM)

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦ ¹× µ¿Ç⠺м®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
  • ¿µÇ⠺м®
  • ½ÃÀå µ¿Çâ
  • ÁÖ¿ä ¹ßÀü
  • ±ÔÁ¦ ½Ã³ª¸®¿À
  • Àμö ¹× Á¦ÈÞ ½Ã³ª¸®¿À
  • ÀÚ±Ý Á¶´Þ ¹× ÅõÀÚ
  • PEST ºÐ¼®
  • Porter's Five Forces ºÐ¼®

Á¦4Àå ¼¼°èÀÇ ´ã°ü¾Ï ½ÃÀå : COVID-19 ÆÒµ¥¹ÍÀÇ ¿µÇâ

  • ÀüüÀûÀÎ ¿µÇâ
  • Á¤ºÎÀÇ ´ëó
  • COVID-19¿¡ ÀÇÇÑ ½ÃÀå¿¡ ´ëÇÑ ¿µÇâ

Á¦5Àå ¼¼°èÀÇ ´ã°ü¾Ï ½ÃÀå : Ä¡·á À¯Çüº°(2020-2032³â)

  • È­ÇÐ ¿ä¹ý
  • Ç¥Àû ¿ä¹ý
  • ¸é¿ª ¿ä¹ý
  • ±âŸ

Á¦6Àå ¼¼°èÀÇ ´ã°ü¾Ï ½ÃÀå : À¯Åë ä³Îº°(2020-2032³â)

  • ¿ø³» ¾à±¹
  • ¼Ò¸Å ¾à±¹
  • ¿Â¶óÀÎ ¾à±¹

Á¦7Àå ¼¼°èÀÇ ´ã°ü¾Ï ½ÃÀå : Áö¿ªº°(2020-2032³â)

  • ºÏ¹Ì
  • ¶óƾ¾Æ¸Þ¸®Ä«
  • À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áßµ¿
  • ¾ÆÇÁ¸®Ä«

Á¦8Àå °æÀï ±¸µµ

  • ±â¾÷ ÇÁ·ÎÆÄÀÏ
    • F. Hoffmann-La Roche Ltd
    • Sanofi
    • Pfizer Inc.
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • Merck &Co., Inc.
    • Novartis AG
    • Celgene Corporation
    • Johnson &Johnson Services, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Bayer AG
    • Fresenius Kabi AG
    • Mylan NV
    • ConMed Corporation
    • Boston Scientific Corporation
    • Taiho Pharmaceutical Co., Ltd.
    • Incyte Corporation

Á¦9Àå ºÐ¼®°¡ Ãßõ

  • ¿î¸íÀÇ ¿ø
  • ¾Ö³Î¸®½ºÆ®ÀÇ °ßÇØ
  • Coherent Opportunity Map(COM)

Á¦10Àå Âü°í¹®Çå ¹× Á¶»ç¹æ¹ý

  • Âü°í¹®Çå
  • Á¶»ç¹æ¹ý
AJY 25.04.02

Global Bile Duct Cancer Market is estimated to be valued at USD 4.03 Bn in 2025 and is expected to reach USD 7.18 Bn by 2032, growing at a compound annual growth rate (CAGR) of 8.6% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 4.03 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 8.60% 2032 Value Projection: USD 7.18 Bn
Figure. Bile Duct Cancer Market Share (%), By Region 2025
Bile Duct Cancer Market - IMG1

Bile duct cancer, also known as cholangiocarcinoma, is a rare type of cancer that forms in the bile duct. The bile duct is a tube that connects the liver and gallbladder to the small intestine. Bile duct cancer occurs when the cells that line the bile ducts become abnormal and grow uncontrollably, forming a tumor. Key risk factors for developing bile duct cancer include primary sclerosing cholangitis (PSC), an inflammatory bowel disease, liver flukes, and certain congenital abnormalities of the bile ducts. Symptoms may include jaundice, itching, abdominal pain, weight loss, and pale stools. Diagnosis usually involves imaging tests such as ultrasound, CT scan, and MRI scans, as well as biopsy. Treatment options depend on the stage of cancer and include surgery, radiation therapy, chemotherapy, and targeted therapy. However, bile duct cancer has a poor prognosis with low survival rates due to difficulties in early detection and slow growth nature of the tumors.

Market Dynamics:

Global bile duct cancer market growth is primarily driven by increasing prevalence of risk factors such as PSC and liver flukes infections. According to the Center for Disease Control and Prevention (CDC), PSC affects around 30,000 people in the U.S. Insufficient understanding and delays in diagnosing bile duct cancer also contribute to late-stage diagnosis, thus, driving the market growth. Moreover, rising research funding towards targeted drug development for improving the bile duct cancer treatment outcomes can offer lucrative opportunities for market players. However, low disease awareness and complexity in surgical procedures can hamper the market growth.

Key Features of the Study:

  • This report provides in-depth analysis of the global bile duct cancer market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global bile duct cancer market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Eli Lilly, F. Hoffmann-La Roche Ltd., Pfizer Inc., Sanofi, and Bristol-Myers Squibb Company
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • Global bile duct cancer market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bile duct cancer market

Detailed Segmentation-

  • By Treatment Type
    • Chemotherapy
    • Gemcitabine
    • Cisplatin
    • Oxaliplatin
    • Capecitabine
    • 5 fluorouracil (5-FU)
    • Targeted Therapy
    • Pemigatinib
    • Infigratinib (Phase 3)
    • Ivosidenib (Phase 3)
    • Immunotherapy
    • (Pembrolizumab (Phase 3))

Others

  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Region:
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East
    • Africa
  • Company Profiles:
    • Hoffmann-La Roche Ltd
    • Sanofi
    • Pfizer Inc.
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • Merck & Co., Inc.
    • Novartis AG
    • Celgene Corporation
    • Johnson & Johnson Services, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Bayer AG
    • Fresenius Kabi AG
    • Mylan N.V.
    • ConMed Corporation
    • Boston Scientific Corporation
    • Taiho Pharmaceutical Co., Ltd.
    • Incyte Corporation

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Treatment Type
    • Market Snapshot, By Distribution Channel
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Opportunities
  • Impact Analysis
  • Market Trends
  • Key Developments
  • Regulatory Scenario
  • Acquisitions and Partnerships Scenario
  • Funding and Investments
  • PEST Analysis
  • Porter's Analysis

4. Global Bile Duct Cancer Market - Impact of Coronavirus (COVID-19) Pandemic

  • Overall Impact
  • Government Initiatives
  • COVID-19 Impact on the Market

5. Global Bile Duct Cancer Market, By Treatment Type, 2020 - 2032, (USD Bn)

  • Overview
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Chemotherapy
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Gemcitabine
    • Cisplatin
    • Oxaliplatin
    • Capecitabine
    • 5 fluorouracil (5-FU)
  • Targeted Therapy
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Pemigatinib
    • Infigratinib (Phase 3)
    • Ivosidenib (Phase 3)
  • Immunotherapy
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • (Pembrolizumab (Phase 3)
  • Others
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Bile Duct Cancer Market, By Distribution Channel, 2020 - 2032, (USD Bn)

  • Overview
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Hospital Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Retail Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Online Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Bile Duct Cancer Market, By Region, 2020 - 2032, (USD Bn)

  • Introduction
    • Market Share Analysis, By Region, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, For Region, 2021-2032
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
      • U.K.
      • Germany
      • Italy
      • France
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
      • China
      • India
      • Japan
      • ASEAN
      • Australia
      • South Korea
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Bn)
      • North Africa
      • Central Africa
      • South Africa

8. Competitive Landscape

  • Company Profiles
    • F. Hoffmann-La Roche Ltd
      • Company Highlights
      • Method Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Sanofi
      • Company Highlights
      • Method Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Pfizer Inc.
      • Company Highlights
      • Method Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Bristol-Myers Squibb Company
      • Company Highlights
      • Method Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Eli Lilly and Company
      • Company Highlights
      • Method Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Merck & Co., Inc.
      • Company Highlights
      • Method Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Novartis AG
      • Company Highlights
      • Method Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Celgene Corporation
      • Company Highlights
      • Method Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Johnson & Johnson Services, Inc.
      • Company Highlights
      • Method Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Teva Pharmaceutical Industries Ltd.
      • Company Highlights
      • Method Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Bayer AG
      • Company Highlights
      • Method Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Fresenius Kabi AG
    • Mylan N.V.
    • ConMed Corporation
    • Boston Scientific Corporation
    • Taiho Pharmaceutical Co., Ltd.
    • Incyte Corporation

9. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map
  • References and Research Methodology
  • References
  • Research Methodology
  • About us and Sales Contact
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦